Deep Vein Thrombosis - Pipeline Insight, 2024

This “Deep Vein Thrombosis - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Deep Vein Thrombosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Deep Vein Thrombosis Understanding

Deep Vein Thrombosis: Overview

Deep vein thrombosis (DVT) is a medical condition that occurs when a blood clot forms in a deep vein. These clots usually develop in the lower leg, thigh, or pelvis, but they can also occur in the arm. The most serious complication of DVT happens when a part of the clot breaks off and travels through the bloodstream to the lungs, causing a blockage called pulmonary embolism (PE). If the clot is small, and with appropriate treatment, people can recover from PE. However, there could be some damage to the lungs. If the clot is large, it can stop blood from reaching the lungs and is fatal. Medication is used to prevent and treat DVT. Compression stockings (also called graduated compression stockings) are sometimes recommended to prevent DVT and relieve pain and swelling. These might need to be worn for 2 years or more after having DVT. In severe cases, the clot might need to be removed surgically.

Deep Vein Thrombosis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Deep Vein Thrombosis pipeline landscape is provided which includes the disease overview and Deep Vein Thrombosis treatment guidelines. The assessment part of the report embraces, in depth Deep Vein Thrombosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Deep Vein Thrombosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Deep Vein Thrombosis R&D. The therapies under development are focused on novel approaches to treat/improve Deep Vein Thrombosis.

Deep Vein Thrombosis Emerging Drugs Chapters

This segment of the Deep Vein Thrombosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Deep Vein Thrombosis Emerging Drugs

CM20201: CarbomimeticsCurrently in the preclinical phase, CM20201, an efficient small glyco-drug with selective activity inhibition of Factor Xa, would be used in a first place for oncology related Deep Vein Thrombosis (DVT). Today, anticoagulants are the reference treatment but display major risk of uncontrollable life threatening bleeding.

Abelacimab: Anthos TherapeuticsAbelacimab, is an investigational monoclonal antibody that achieves profound suppression of the novel antithrombotic target Factor XI through dual activity against both Factor XI itself and its activated form, Factor XIa. Abelacimab represents a promising next-generation anticoagulant with the potential to provide ‘hemostasis-sparing anticoagulation’: vital protection from arterial and venous thromboembolic events with a reduced risk of clinically significant bleeding.Currently the drug is in Phase III stage of Clinical trial evluation for the treatment of Deep Venous Thrombosis.

Deep Vein Thrombosis: Therapeutic Assessment

This segment of the report provides insights about the different Deep Vein Thrombosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Deep Vein Thrombosis

There are approx. 5+ key companies which are developing the therapies for Deep Vein Thrombosis. The companies which have their Deep Vein Thrombosis drug candidates in the most advanced stage, i.e. phase III include,Anthos Therapeutics.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Deep Vein Thrombosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Deep Vein Thrombosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Deep Vein Thrombosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Deep Vein Thrombosis drugs.

Deep Vein Thrombosis Report Insights

• Deep Vein Thrombosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Deep Vein Thrombosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Deep Vein Thrombosis drugs?
• How many Deep Vein Thrombosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Deep Vein Thrombosis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Deep Vein Thrombosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Deep Vein Thrombosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Carbomimetics
• GlycoMimetics
• Marizyme
• Boehringer Ingelheim
• Bio-Synectics,Inc.

Key Products

• CM20201
• Uproleselan
• MB104
• Alteplase
• BS-112